Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketodex
- Development stage
- Phase 4
- Lead developer
- Naveen Poonai
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Ketodex is an investigational combination therapy consisting of intranasal dexmedetomidine and intranasal ketamine, currently being evaluated for procedural sedation and analgesia in pediatric patients. The combination leverages the synergistic effects of dexmedetomidine, a selective alpha-2 adrenergic agonist that provides sedation and analgesia without significant respiratory depression, and ketamine, a dissociative anesthetic that primarily acts as an NMDA receptor antagonist. Administered via a mucosal atomization device (MAD), Ketodex is designed to provide effective sedation for procedures such as the closed reduction of fractures and dislocations in children, thereby avoiding the pain and distress associated with intravenous catheter insertion. It is currently being studied in a multicenter, adaptive randomized controlled trial led by Dr. Naveen Poonai to determine optimal dosing and non-inferiority to standard intravenous ketamine.
- Other names
- intranasal dexmedetomidine plus ketamineIN Ketodexdexmedetomidine + ketamine
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)NeuraminidaseSCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)
Beyond the preview
Go deeper on Ketodex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ketodex.